Phase 2 Psoriatic Arthritis Trial, Recruiting NCT07321873 Sponsor: Janssen Research & Development, LLC Condition: Psoriatic Arthritis
Back to Psoriatic Arthritis

Phase 2 Psoriatic Arthritis Trial, Recruiting

NCT07321873
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with psoriatic arthritis (PsA) for at least 3 months before the study starts, and who meet a standard set of classification criteria for PsA at the screening visit
  • People with active PsA, meaning at least 3 swollen joints and at least 3 tender joints (checked at two separate visits), along with a blood marker of inflammation (CRP) above a certain level
  • People whose PsA falls into at least one of these patterns: involvement of the finger or toe joints closest to the nails, arthritis in many joints without certain lumps under the skin, uneven joint involvement on different sides of the body, or spine involvement alongside joint inflammation
  • People who have active plaque psoriasis, shown by at least one psoriasis patch of 2 centimetres or larger, or nail changes typical of psoriasis
  • Women who could become pregnant must have a negative pregnancy blood test at the screening visit and a negative pregnancy urine test at the first study visit before receiving any study treatment

Who may not be able to join:

  • People who have a non-plaque form of psoriasis, such as the type that causes widespread redness, small drop-shaped patches, or pus-filled spots
  • People who have, or have a history of, serious, worsening, or poorly controlled conditions affecting the kidneys, liver, heart, blood vessels, lungs, digestive system, hormones, nervous system, blood, joints (other than PsA), mental health, urinary system, or metabolism
  • People who are known or suspected to be allergic or sensitive to the study drug (JNJ-88545223) or any of its ingredients, or who have had a severe allergic reaction, severe swelling, or anaphylaxis to any medication or food in the past
  • People who have fibromyalgia or osteoarthritis symptoms that, in the opinion of the study doctor, could make it difficult to accurately measure how well the treatment is working
  • People who currently have cancer, or who have had cancer within the 5 years before the screening visit

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Phone: 844-434-4210

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
15 January 2026
Est. completion
28 June 2027

Where this trial is recruiting

🇨🇳 China 🇨🇿 Czechia 🇩🇪 Germany 🇭🇺 Hungary 🇯🇵 Japan 🇵🇱 Poland 🇪🇸 Spain 🇺🇸 United States

Primary endpoints

Proportion of Participants who Achieved an American College of Rheumatology (ACR) 50 Response at Week 16

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov